EMD-13869

Single-particle
3.3 Å
EMD-13869 Deposition: 12/11/2021
Map released: 15/12/2021
Last modified: 23/10/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links

EMD-13869

COVOX-222 fab in complex with SARS-CoV-2 beta-Spike glycoprotein

EMD-13869

Single-particle
3.3 Å
EMD-13869 Deposition: 12/11/2021
Map released: 15/12/2021
Last modified: 23/10/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Sample Organism: Severe acute respiratory syndrome coronavirus 2, Homo sapiens
Sample: COVOX-222 fab in complex with SARS-CoV-2 beta-Spike glycoprotein
Fitted models: 7q9g (Avg. Q-score: 0.341)

Deposition Authors: Duyvesteyn HME , Ren J , Stuart DI
The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants.
PUBMED: 34921776
DOI: doi:10.1016/j.chom.2021.11.013
ISSN: 1934-6069
Abstract:
Alpha-B.1.1.7, Beta-B.1.351, Gamma-P.1, and Delta-B.1.617.2 variants of SARS-CoV-2 express multiple mutations in the spike protein (S). These may alter the antigenic structure of S, causing escape from natural or vaccine-induced immunity. Beta is particularly difficult to neutralize using serum induced by early pandemic SARS-CoV-2 strains and is most antigenically separated from Delta. To understand this, we generated 674 mAbs from Beta-infected individuals and performed a detailed structure-function analysis of the 27 most potent mAbs: one binding the spike N-terminal domain (NTD), the rest the receptor-binding domain (RBD). Two of these RBD-binding mAbs recognize a neutralizing epitope conserved between SARS-CoV-1 and -2, while 18 target mutated residues in Beta: K417N, E484K, and N501Y. There is a major response to N501Y, including a public IgVH4-39 sequence, with E484K and K417N also targeted. Recognition of these key residues underscores why serum from Beta cases poorly neutralizes early pandemic and Delta viruses.